Introduction
Does undetectable MRD meet the key requirements to be used as treatment endpoint?
MRD supersedes CR
The clinical impact of MRD is reproducible in different centers, by molecular and immunophenotypic methods, and in all disease settings
Undetectable MRD is clinically relevant in patients with standard- and high-risk disease
Potential pitfalls of MRD in MM
The quality of BM samples
Patients displaying transient or unsustained MRD negativity
Cases remaining MRD positive at very low levels without disease progression
Persistence of extramedullary disease not detectable in BM aspirates
How to implement MRD in clinical practice?
NCT | Study official title | Country | Technique |
---|---|---|---|
NCT02406144 | Maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and ixazomib after autologous hematopoietic stem cell transplantation in patients With newly diagnosed symptomatic multiple myeloma-duration of maintenance guided by MRD status (GEM2014MAIN) | Spain | NGF |
RADAR* | Risk adapted therapy directed according to response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplantation | UK | N/A |
NCT03490344 | Short course daratumumab in minimal residual disease (MRD) positive myeloma patients after induction therapy with/without consolidative high-dose chemotherapy/autologous stem cell support | USA | FC |
NCT03224507 | Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma (MASTER) | USA | NGS |
NCT03742297* | Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide, and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years | Spain | NGF |
NCT03697655 | Pre-emptive daratumumab therapy of minimal residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR) | Poland | N/A |
NCT03710603 | A phase 3 study comparing daratumumab, VELCADE (Bortezomib), lenalidomide, and dexamethasone (D-VRd) vs VELCADE, lenalidomide, and dexamethasone (VRd) in subjects with previously untreated multiple myeloma who are eligible for high-dose therapy (PERSEUS) | EMN | N/A |
NCT03992170 | A pilot study on the efficacy of daratumumab in multiple myeloma (MM) patients in >VGPR/MRD-positive by next-generation flow (DART4MM) | Italy | FC |
NCT02969837 | Open-label, single-arm, phase 2 study of initial treatment with elotuzumab, carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone (E-KRd) in newly diagnosed, multiple myeloma requiring systemic chemotherapy | USA | NGS and MFC |
NCT04071457 | S1803, phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC study) | USA | NGS |
NCT04096066 | Carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in newly diagnosed myeloma patients not eligible for autologous stem cell transplantation: a randomized phase III trial | Italy | N/A |
NCT03376477 | A randomized, double-blind, placebo-controlled phase II trial of an allogeneic myeloma GM-CSF vaccine with lenalidomide in multiple myeloma patients in complete or near complete | USA | NGS |
NCT04108624 | A multimodality approach to minimal residual disease detection to guide post-transplant maintenance therapy in multiple myeloma (MRD2STOP) | USA | NGS |
NCT04221178 | A single-arm, prospective atudy of maintenance therapy cessation for patients with multiple myeloma in sustained MRD-negative remissions | USA | NGF |
NCT04140162 | Phase 2 study with minimal residual disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma (MM) with upfront daratumumab-based therapy | USA | N/A |
Study | Treatment | Outcome | MRD assessment | MRD-negative rate |
---|---|---|---|---|
Transplant-eligible | ||||
HDT vs RVD | HDT: median PFS 50m RVD: median PFS 36m | NGS (10−6)a | HDT 30% RVD 20% | |
CASSIOPEIA (NCT02541383) [10] | D-VTd vs VTd | D-VTD: 18m PFS 93% VTD: 18m PFS 85% | NGF (10−5) | D-VTD 64% VTD 44% |
Transplant-ineligible | ||||
ALCYONE (NCT02195479) [25] | D-VMP vs VMP | D-VMP: median PFS NR VMP: median PFS 18.1m | NGS (10−5) | D-VMP 22.3% VMP 6.2% |
CLARION (NCT01818752) [27] | KMP vs VMP | KMP: median PFS 22.3m VMP: median PFS 22.1m | NGF (10−6) | KMP 15.7% VMP 15.5% |
MAIA (NCT02252172) [26] | DRd vs Rd | DRd: median PFS NR Rd: median PFS 31.9m | NGS (10−5) | DRd 24.2% Rd 7.3% |
Relapse/refractory | ||||
POLLUX (NCT02076009) [30] | DRd vs Rd | DRd: median PFS NR Rd: median PFS 17.5m | NGS (10−5) | DRd 22.4% Rd 4.6% |
CASTOR (NCT02136134) [29] | DVd vs Vd | DVd: median PFS 16.7m Vd: median PFS 7.1m | NGS (10−5) | DVd 11.6% Vd 2.4% |